KRAS and colorectal carcinoma: Comprehensive genomic analysis should be integrated into the routine evaluation of YO-CRC to guide risk stratification and therapeutic decision-making, and future studies should explore novel strategies for improving outcomes in KRAS-mutant and other high-risk molecular subgroups.